-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Reiterates Buy on Johnson & Johnson, Maintains $287 Price Target

Benzinga·10/07/2026 13:05:21
Diffusion vocale
Guggenheim analyst Vamil Divan reiterates Johnson & Johnson (NYSE:JNJ) with a Buy and maintains $287 price target.